Presentation of New Data at EMUC 2024
ImPact Biotech, a clinical-stage biotechnology firm, is making remarkable strides in cancer treatment. The company has recently announced it will present updated interim results from the ENLIGHTED study at the upcoming European Multidisciplinary Congress on Urological Cancers (EMUC 2024). This important event is set to take place in November, where healthcare professionals will gather to discuss innovative treatments and research findings.
Focus on Padeliporfin VTP Therapy
At the heart of ImPact Biotech's research is the Padeliporfin vascular targeted photodynamic (VTP) therapy. This novel approach offers a minimally invasive option for patients struggling with solid tumors, specifically targeting low-grade upper tract urothelial cancer (UTUC). By utilizing specific light wavelengths combined with Padeliporfin, the therapy aims to effectively destroy cancer cells while sparing surrounding healthy tissue.
Details of the Presentation
During EMUC 2024, the presentation will include a poster titled "ENLIGHTED Phase 3 Study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)." The abstract will highlight critical findings from the ongoing Phase 3 trial, which is actively evaluating the effectiveness and safety of Padeliporfin treatment.
Key Presentation Details
The poster will be presented by Gautier Marcq, M.D., M.Sc., and is scheduled for November 9 at 17:30 GMT during the EMUC24 Networking Session. Researchers and healthcare providers attending are expected to gain valuable insights into the ongoing advancements in VTP therapy and its potential benefits for UTUC patients.
About ImPact Biotech
ImPact Biotech stands at the forefront of cancer treatment innovation. The company not only focuses on VTP therapy but is also intensely evaluating other applications of Padeliporfin in various cancers. The company's landmark partnerships with prominent institutions enhance its research capabilities. Their collaborative efforts with the Weizmann Institute of Science and the Memorial Sloan Kettering Cancer Center further signify their commitment to creating effective cancer solutions.
Advancements and Future Plans
Currently, ImPact Biotech's Padeliporfin VTP therapy is undergoing comprehensive investigation. Following the ongoing Phase 3 clinical trial for low-grade UTUC, plans are in motion for additional studies aimed at high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). These developments illustrate the versatility of the therapy and the company’s dedication to tackling various forms of cancer with innovative techniques.
Contact Information
For further details regarding the study and company initiatives, ImPact Biotech encourages interested parties to reach out to their team. The company’s Global Head of Business Development, Guy Schmidt, can be contacted directly at guy.schmidt@impactbiotech.com for business inquiries. For those wishing to explore precision oncology solutions, Josh Rappaport from Precision AQ can also be reached at josh.rappaport@precisionaq.com.
Frequently Asked Questions
What is the ENLIGHTED study?
The ENLIGHTED study is a Phase 3 trial evaluating the safety and efficacy of Padeliporfin therapy in treating patients with low-grade UTUC.
When will the results be presented?
The results are set to be presented on November 9, 2024, at the EMUC 2024 congress in Lisbon.
Who is leading the presentation?
The presentation will be led by Gautier Marcq, M.D., M.Sc.
What are the potential benefits of Padeliporfin VTP therapy?
This therapy aims to selectively target and ablate cancer cells while minimizing damage to surrounding healthy tissues.
How can I learn more about ImPact Biotech?
For more information, visit their website at www.impactbiotech.com.
